Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab and Anlotinib in Advanced HCC
NCT05453383Phase 2Unknown
- Sponsor
- Shenfeng Biological
- Start
- Jul 2022
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab, anlotinib in hepatocellular carcinoma (HCC), sponsored by Shenfeng Biological. Status: unknown.
02
Drugs
toripalimabanlotinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05453383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05453383.